Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 11 , ISSUE 3 ( July, 2007 ) > List of Articles

ORIGINAL ARTICLE

Treatment of ventilator-associated pneumonia with piperacillin-tazobactum and amikacin vs cefepime and levofloxacin: A randomized prospective study

Parul, Syed Moied Ahmed, J. Choudhary, M. Ahmed, V. Arora, S. Ali

Keywords : Antibiotics, cefepime, levofloxacin, piperacillin-tazobactam, ventilator associated pneumonia

Citation Information : P, Ahmed SM, Choudhary J, Ahmed M, Arora V, Ali S. Treatment of ventilator-associated pneumonia with piperacillin-tazobactum and amikacin vs cefepime and levofloxacin: A randomized prospective study. Indian J Crit Care Med 2007; 11 (3):117-121.

DOI: 10.4103/0972-5229.35084

License: CC BY-ND 3.0

Published Online: 00-07-2007

Copyright Statement:  Copyright © 2007; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Study Objectives: To compare the survival benefits and cost effectiveness of cefepime-levofloxacin (C-L) as an alternative empirical antibiotic therapy for ventilator associated pneumonia (VAP) with the most widely recommended combination of piperacillin-tazobactam and amikacin (P-T-A). Design: Prospective, observational, cohort study. Materials and Methods: A total number of 879 patients were admitted in the ICU during 1st April 2004 to 31 st March 2005 and were screened for the study. Ninety-three patients were clinically suspected to develop early onset VAP. The patients were randomly divided into two groups receiving Cefepime-Levofloxacin (C-L) or Piperacillin-Tazobactam-Amikacin (P-T-A) as empirical antibiotic therapy. Treatment outcome was compared between the groups, which included ICU mortality, duration of mechanical ventilation, duration of ICU stay and total cost incurred on antibiotics. Results: The epidemiological characteristics including mean age and APACHE II score were comparable between the two groups. The mortality rates in the two groups were similar. The duration of mechanical ventilation was shorter in C-L group (5-8 days) as compared to P-T-A group (6-11 days). Also, the mean duration of ICU stay was reduced in C-L group (16±2.1 days) as compared to P-T-A group (19±3.4 days). Further, the overall cost of antibiotics in C-L group was 1/3 rd of the cost in P-T-A group. Eleven patients were found to be receiving inappropriate antibiotics and seven patients developed ARF during the course of antibiotic therapy. These patients were excluded from the study. Conclusion: Cefepime-Levofloxacin combination is an effective alternative to piperacillin-tazobactam-amikacin for empirical treatment of VAP. It reduces the duration of mechanical ventilation, number of days of ICU stay and overall cost of antibiotics


PDF Share
  1. Effect of ventilator-associated pneumonia on mortality and morbidity. Am J Respir Crit Care Med 1996;154:91-7.
  2. Incidence, etiology and outcome of nosocomial pneumonia in mechanically ventilated patients. Chest 1991;100:439-44.
  3. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit: ICU-Acquired Pneumonia study group. Intensive Care Med 1996;22:387-94.
  4. Antibiotic misuse in two clinical situations: Positive blood cultures and administration of aminoglycoside. Rev Infect Dis 1991;13:405-12.
  5. Rotation and restricted use of antibiotics in a Medical Intensive care unit. Am J Respir Crit Care Med 2000;162:837-43.
  6. Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia. Chest 2003;123:835-44.
  7. Evaluation of the in vitro activity of six broad-spectrum β -lactam antimicrobial gents tested against recent clinical isolates from India: A survey of ten medical center laboratories. Diag Microbiol Infect Dis 2002;44:367-77.
  8. Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J Antimicrob Chemother 2002;50:1045-9.
  9. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-74.
  10. Treatment of severe Pneumonia in hospitalized patients: Results of multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastin. Antimicrob Agents Chemother 1994;38:547-57.
  11. Monotherapy vs β -lactam-aminoglycoside combination treatment for Gram-negative bacteremia: A prospective, observational study. Antimicrob Agents Chemother 1997;41:1127-33.
  12. A consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med 1995;153:1711-25.
  13. Hospital-acquired pneumonia: Risk-factors, microbiology and treatment. Chest 2001;119:373S-84S.
  14. Cefepime microbiologic profile and update. Pediatr Infect Dis J 2001;20:331-6.
  15. Incidence and risk factors for ventilator associated pneumonia in critically ill patients. Ann Intern Med 1998;129:433-40.
  16. Risk factors for ICU-acquired pneumonia. JAMA 1998;279:1605-6.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.